Upstart Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Upstart Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.04B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $636.53M | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | $513.56M | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $842.44M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $848.59M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $233.42M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $164.19M | Feb 18, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $907.27M | Feb 16, 2023 |
| FY2022 | Dec 31, 2021 | $801.28M | Feb 16, 2023 |
| FY2022 | Dec 31, 2020 | $228.60M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $159.85M | Feb 18, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.60M | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | ($128.58M) | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | ($240.13M) | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | ($108.67M) | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $135.44M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $5.98M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | ($466.0K) | Feb 18, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.63M | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | ($172.86M) | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | ($256.53M) | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | ($113.86M) | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $140.88M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $11.77M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | ($4.58M) | Feb 18, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $257.60M | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $253.65M | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | $280.14M | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $237.25M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $134.00M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $38.80M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $18.78M | Feb 18, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($147.73M) | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $186.33M | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | ($111.71M) | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | ($657.86M) | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $168.35M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $15.70M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $31.58M | Feb 18, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $347.0K | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $837.0K | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | $1.53M | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | $8.83M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $8.43M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $1.36M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $4.00M | Feb 18, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.97B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $2.37B | Feb 10, 2026 |
| FY2024 | Dec 31, 2023 | $2.02B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.94B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.82B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $477.26M | Feb 18, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.18B | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $1.73B | Feb 10, 2026 |
| FY2024 | Dec 31, 2023 | $1.38B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.26B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.01B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $177.00M | Feb 18, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $798.82M | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $633.22M | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | $635.31M | Feb 10, 2026 |
| FY2025 | Dec 31, 2022 | $672.44M | Feb 10, 2026 |
| FY2024 | Dec 31, 2021 | $807.08M | Feb 14, 2025 |
| FY2023 | Dec 31, 2020 | $300.25M | Feb 15, 2024 |
| FY2022 | Dec 31, 2019 | ($61.69M) | Feb 16, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.06M | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $67.06M | Feb 10, 2026 |
| FY2024 | Dec 31, 2023 | $67.06M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $67.06M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $67.06M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Feb 18, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($357.56M) | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | ($411.16M) | Feb 10, 2026 |
| FY2024 | Dec 31, 2023 | ($282.58M) | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | ($42.44M) | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $66.22M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | ($69.22M) | Feb 18, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $652.39M | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | $788.42M | Feb 10, 2026 |
| FY2024 | Dec 31, 2023 | $368.41M | Feb 14, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 18, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 10, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Feb 10, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 18, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 98.03M | Feb 10, 2026 |
| FY2025 | Dec 31, 2024 | 93.47M | Feb 10, 2026 |
| FY2024 | Dec 31, 2023 | 86.33M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | 81.26M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | 83.66M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | 73.31M | Feb 18, 2022 |